Advertisement

Topics

Hemispherx Biopharma Company Profile

21:32 EDT 23rd September 2017 | BioPortfolio

Hemispherx Biopharma, Inc. has devoted nearly three decades to exploring, understanding, and mastering the mechanism of RNA technology. The Company's longevity as a biomedical research and drug development institution, coupled with its record of tremendous enduring scientific achievement is evidence of Hemispherx’s long-term commitment to this promising new class of drugs and to bring new therapeutic choices to the global community.



Using nucleic acid technologies to develop therapeutic products for the treatment of viral disease and certain cancers, the company has pioneered a new class of specifically-configured ribonucleic acid (RNA) which targets the treatment of Chronic Fatigue Syndrome (CFS), HIV associated disorders, chronic hepatitis B & C infection and cancers which include kidney cancer and metastatic malignant melanoma. Hemispherx with its predecessor, HEM Pharmaceuticals has nearly 30 years of RNA technology and is believed to be the only biotechnology company using nucleic acid drug methodology targeting the body's natural anti-viral defense system.

Location

One Penn Center
1617 JFK Blvd., 6th Floor
Philadelphia
PA
19103
United States of America

Contact

Phone: (215) 988-0080
Fax: (215) 988-1739
Email: info@hemispherx.net


News Articles [1618 Associated News Articles listed on BioPortfolio]

Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology

PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to bolster its scientific capabilities by ex...

Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities

PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to build its manufacturing and scientific capa...

Hemispherx Biopharma's (HEB) CEO Thomas Equels on Q2 2017 Results - Earnings Call Transcript

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017

PHILADELPHIA, May 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2017. The net loss was approximately $2,821...

Faruqi & Faruqi, LLP Encourages Investors Who Suffered $50,000 or More In Losses Investing In Hemispherx Biopharma, Inc. To Contact The Firm

NEW YORK, Dec. 28, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Hemispherx Biopharma, Inc. ("Hemispherx" o...

Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.

SAN DIEGO and PHILADELPHIA, Jan. 17, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that purchasers of Hemispherx Biopharma, Inc. (NYSE: HEB) ("Hemispherx" or th...

Hemispherx Biopharma Inc HEB Financial and Strategic SWOT Analysis Review [Report Updated: 05072017] Prices from USD $125

Hemispherx Biopharma Inc HEB Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by ...

Hemispherx Repurposes Ampligen In Immuno-Oncology

  Life Sciences Jobs   ...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]

CARDENE® SR

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Applications of Raman Spectroscopy in Biopharmaceutical Manufacturing: A Short Review.

The production of active pharmaceutical ingredients (APIs) is currently undergoing its biggest transformation in a century. The changes are based on the rapid and dramatic introduction of protein- and...

On-line prediction of the glucose concentration of CHO cell cultivations by NIR and Raman spectroscopy: Comparative scalability test with a shake flask model system.

In this study, near-infrared (NIR) and Raman spectroscopy were compared in parallel to predict the glucose concentration of Chinese hamster ovary cell cultivations. A shake flask model system was used...

Multiplexing N-Glycan analysis by DNA analyzer.

Analysis of N-glycan structures has been gaining attentions over the years due to their critical importance to biopharma based applications and growing roles in biological research. Glycan profiling i...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [124 Associated Companies listed on BioPortfolio]

Hemispherx Biopharma

Hemispherx Biopharma, Inc. has devoted nearly three decades to exploring, understanding, and mastering the mechanism of RNA technology. The Company's longevity as a biomedical research and drug develo...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

Exostar and SAFE-BioPharma Association

SAFE-BioPharma manages the SAFE-BioPharma global digital identity and digital signatures standard, developed for and used extensively throughout the biopharmaceutical industry. LO...

More Information about "Hemispherx Biopharma" on BioPortfolio

We have published hundreds of Hemispherx Biopharma news stories on BioPortfolio along with dozens of Hemispherx Biopharma Clinical Trials and PubMed Articles about Hemispherx Biopharma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hemispherx Biopharma Companies in our database. You can also find out about relevant Hemispherx Biopharma Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...


Corporate Database Quicklinks



Searches Linking to this Company Record